PHILADELPHIA (PRWEB) August 05, 2019
ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced that Timothy Kulbago, Vice President, Imaging has been named one of the 100 most inspiring individuals in the life-sciences industry by PharmaVoice.
Representing a broad cross-section of industry sectors, the PharmaVoice 100 honorees are selected based on how they have inspired their colleagues and affected positive changes in their organizations, as well as their involvement in community and philanthropic activities.
“We’re pleased to honor Tim as he truly represents the spirit of the PharmaVoice 100,” said Taren Grom, Editor and Cofounder of PharmaVOICE. “His contributions – and those of his team – are really making a difference in helping the industry best serve its ultimate stakeholders: patients.”
Kulbago is being recognized for his unwavering commitment to delivering innovative solutions that help ERT’s clients improve the quality and process of collecting clinical trial imaging data.Tim’s team provides customized image and data analysis, delivering objective safety and efficacy evidence that meets regulatory expectations, reduces development costs and speeds time to market entry.
“Tim’s exemplary leadership and ability to inspire innovative thinking among his team enables ERT to continually exceed our customers’ expectations and deliver the right solutions to meet their complex imaging needs,” said Jim Corrigan, President and CEO of ERT. “We’re very proud of his accomplishments and applaud him – as well as all of the individuals being recognized – for this well-deserved recognition.”
For more information on ERT’s advanced software, engineering and imaging expertise visit ert.com/imaging.
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so it can adapt without compromising standards.
Powered by the company’s EXPERT® technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. Since 2013, more than half of all FDA drug approvals came from ERT-supported studies. Pharma companies, biotechs and CROs have relied on ERT solutions across 15,000 studies, spanning more than four million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly ─ and with confidence.